All In Biotech

Drug Trial Radar · NCT03568318

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,533 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,533

Actual

Start

Aug 9, 2018

Primary completion

Feb 16, 2021

Study completion Oct 23, 2030

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Jun 26, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Conditions

  • Atopic Dermatitis

Interventions

  • PlaceboDrug

    Tablets taken orally once a day

  • UpadacitinibDrug

    Tablets taken orally once a day

  • Topical corticosteroids (TCS)Drug

    Topical corticosteroids will be applied in a stepdown regimen, starting with medium potency once daily to areas with active lesions until lesions are clear or almost clear, or for 3 consecutive weeks, whichever is shorter; then low potency topical corticosteroids once daily. If lesions return or persist, this step-down approach will be repeated until lesion resolution or evidence of local or systemic topical corticosteroids toxicity. Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as low potency topical corticosteroid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16Time frame: Baseline and Week 16
  2. Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16Time frame: Baseline and Week 16

Locations

193 sites in 24 countries. Site status is shown where the registry gives one.

  • Total Skin and Beauty Derm Ctr /ID# 200548

    Birmingham, Alabama

  • Clinical Research Center AL /ID# 201865

    Birmingham, Alabama

  • ACCEL Research Sites /ID# 213364

    Birmingham, Alabama

  • Advanced Dermatology and Skin Care Centre /ID# 213550

    Mobile, Alabama

  • Alliance Dermatology and MOHs Center, PC /ID#200540

    Phoenix, Arizona

  • Arizona Research Center, Inc. /ID# 200546

    Phoenix, Arizona

  • Clear Dermatology & Aesthetics Center /ID# 201257

    Scottsdale, Arizona

  • University of Arizona /ID# 201059

    Tucson, Arizona

  • Bakersfield Derma & Skin Cance /ID# 200892

    Bakersfield, California

  • Mosaic Dermatology /ID# 200553

    Beverly Hills, California

  • University of California Irvine /ID# 200902

    Irvine, California

  • Therapeutics Clinical Research /ID# 200593

    San Diego, California

  • Stanford University /ID# 200597

    Stanford, California

  • Duplicate_University of Colorado Anchutz Medical Campus /ID# 202822

    Aurora, Colorado

  • Colorado Center for Dermatology, PLLC /ID# 203626

    Centennial, Colorado

  • Duplicate_Western States Clinical Research, Inc. /ID# 201702

    Wheat Ridge, Colorado

  • Dermatology Physicians of Connecticut /ID# 201004

    Shelton, Connecticut

  • Clearlyderm Dermatology /ID# 207709

    Boca Raton, Florida

  • Skin Care Research, LLC /ID# 200812

    Boca Raton, Florida

  • Clinical Research of West Florida, Inc /ID# 203643

    Clearwater, Florida

  • Florida Academic Centers Research and Education /ID# 200544

    Coral Gables, Florida

  • Tory P Sullivan, MD PA /ID# 201174

    North Miami Beach, Florida

  • Park Avenue Dermatology, PA /ID# 201012

    Orange Park, Florida

  • Precision Clinical Research /ID# 208734

    Sunrise, Florida

  • Advanced Clinical Research at Treasure Valley Dermatology & Skin Cancer Center /ID# 203628

    Boise, Idaho

  • Northwestern University Feinberg School of Medicine /ID# 201646

    Chicago, Illinois

  • Northshore University Health System Dermatology Clinical Trials Unit /ID# 200556

    Skokie, Illinois

  • DuPage Medical Group /ID# 202065

    Wheaton, Illinois

  • Deaconess Clinic Downtown /ID# 201001

    Evansville, Indiana

  • Indiana University /ID# 200515

    Indianapolis, Indiana

  • Epiphany Dermatology of Kansas LLC /ID# 203026

    Overland Park, Kansas

  • ORA, Inc. /ID# 202824

    Andover, Massachusetts

  • Tufts Medical Center /ID# 200570

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center /ID# 200545

    Boston, Massachusetts

  • Clin Res Inst of Michigan, LLC /ID# 208020

    Chesterfield, Michigan

  • Michigan Center for Research Company /ID# 200560

    Clarkston, Michigan

  • MediSearch Clinical Trials /ID# 201006

    Saint Joseph, Missouri

  • Skin Specialists, PC /ID# 200573

    Omaha, Nebraska

  • Dartmouth-Hitchcock Medical Center /ID# 200918

    Lebanon, New Hampshire

  • Psoriasis Treatment Center of Central New Jersey /ID# 200714

    East Windsor, New Jersey

Showing 40 of 193 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.